Medicus Pharma Ltd. MDCX
1.89 USD +0.04 (+2.16%)
Nov 6, 2026, 3:13 PM EST
1.81 Day range 1.95
1.70 52-week range 127.50
- YTD
- -97.53%
- 1 year
- -98.44%
- Market cap
- 3.60M
- EPS (ttm)
- -119.00
- YTD return
- -97.53%
- 1-year return
- -98.44%
- Volume
- 24.75K
- Avg volume
- 110.49K
- Open
- 1.85
- Previous close
- 1.85
- Day's range
- 1.81 – 1.95
- 52-week range
- 1.70 – 127.50
- Analysts
- Buy
- Price target
- 7.81 (+313.0%)
5D +0.03 (+1.61%)
Key statistics
- Price / sales
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- 0
- Total cash
- 0
- Total debt
- 0
- Return on equity
- 0.00%
- 50-day average
- 2.52
- 200-day average
- 2.52
Analyst view
Consensus: buy
Buy
Price target (mean) 7.81 +313.0% upside
Now 1.89
- Target (low)
- 5.61
- Target (mean)
- 7.81
- Target (high)
- 10.00
Ratings (0m) 1 1 buy · 0 hold · 0 sell
- Strong buy1
- Buy0
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
MDCX Revenue — quarterly 0
MDCX Net income — quarterly -11.68M
MDCX EPS — quarterly -10.50
News
Medicus Pharma to Present at BIO-Europe 2026 
Medicus Pharma to Host Third Quarter 2026 Financial Performance and Business Update Call on November 9, 2026 
Medicus Pharma Announces Proposed SkinJect® Business Combination and Concurrent Financing 
Dow Falls Over 100 Points; US Initial Jobless Claims Decline 
Why Applied Digital Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket 
Medicus Pharma (MDCX) Shares Fall 24% After Hours: Here's Why 
12 Health Care Stocks Moving In Wednesday's After-Market Session 
Medicus Pharma Files Optimized Seamless Phase 2b/3 Registration-Intent Protocol To FDA For Teverelix To Treat Advanced Prostate Cancer 
Medicus Pharma Optimizes Portfolio Strategy With High-Value Focus 
Medicus Pharma And Yorkville Mutually Agree To Terminate Standby Equity Purchase Agreement For Up To $15M Of Stock
Your note
Sign in to keep a note on MDCX — it syncs with the Stock Master app.